Genmab A/S (NASDAQ:GMAB) Coverage Initiated at HSBC

Posted by on Jul 16th, 2023

Investment analysts at HSBC initiated coverage on shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) in a report issued on Friday, MarketBeat reports. The brokerage set a “buy” rating on the stock.

Several other research firms have also weighed in on GMAB. UBS Group started coverage on shares of Genmab A/S in a research note on Wednesday, May 31st. They set a “neutral” rating on the stock. Morgan Stanley started coverage on shares of Genmab A/S in a research note on Friday, May 12th. They set an “underweight” rating on the stock. Finally, HC Wainwright lifted their price objective on shares of Genmab A/S from $47.00 to $51.00 in a research note on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Hold” and a consensus price target of $752.20.

Genmab A/S Trading Up 3.3 %

Shares of NASDAQ GMAB opened at $40.02 on Friday. The firm has a market capitalization of $26.43 billion, a PE ratio of 36.05, a price-to-earnings-growth ratio of 1.93 and a beta of 0.92. Genmab A/S has a 1 year low of $31.40 and a 1 year high of $47.50. The firm’s 50-day moving average is $39.36 and its 200-day moving average is $39.21.

Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its quarterly earnings data on Wednesday, May 10th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.04). Genmab A/S had a return on equity of 19.67% and a net margin of 34.34%. The firm had revenue of $411.37 million for the quarter, compared to the consensus estimate of $417.27 million. As a group, equities research analysts anticipate that Genmab A/S will post 0.99 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. First Trust Direct Indexing L.P. raised its holdings in shares of Genmab A/S by 3.1% in the second quarter. First Trust Direct Indexing L.P. now owns 16,986 shares of the company’s stock valued at $646,000 after purchasing an additional 508 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Genmab A/S by 14.6% in the second quarter. Pacer Advisors Inc. now owns 5,810 shares of the company’s stock valued at $221,000 after purchasing an additional 740 shares during the last quarter. Level Four Advisory Services LLC raised its holdings in shares of Genmab A/S by 12.2% in the second quarter. Level Four Advisory Services LLC now owns 9,685 shares of the company’s stock valued at $368,000 after purchasing an additional 1,053 shares during the last quarter. Harbour Capital Advisors LLC raised its holdings in shares of Genmab A/S by 7.3% in the second quarter. Harbour Capital Advisors LLC now owns 7,168 shares of the company’s stock valued at $274,000 after purchasing an additional 490 shares during the last quarter. Finally, Marotta Asset Management acquired a new stake in shares of Genmab A/S in the second quarter valued at approximately $647,000. 6.58% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Articles

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.